Hypertension and incident cardiovascular events following ibrutinib initiation

Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, it has been linked with potentially limiting cardiotoxicity, including emerging reports of profound hypertension (HTN). The long-term incidence, severity, and impact of HTN development with ibrutinib are unknown. Theref...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Dickerson, Tyler, Wiczer, Tracy, Waller, Allyson, Philippon, Jennifer, Porter, Kyle, Haddad, Devin, Guha, Avirup, Rogers, Kerry A., Bhat, Seema, Byrd, John C., Woyach, Jennifer A., Awan, Farrukh, Addison, Daniel
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2019
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6887116/
https://ncbi.nlm.nih.gov/pubmed/31582362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000840
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы